Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.
Chimeric Therapeutics Ltd. announced the quotation of 5,435,254 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of August 7, 2025. This move is part of previously announced transactions and is expected to enhance the company’s capital structure, potentially impacting its market positioning and stakeholder interests.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative therapies. The company is primarily engaged in the research and development of chimeric antigen receptor T cell (CAR-T) therapies, targeting various forms of cancer.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.75M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.